a subgroup analysis of majestec-1: teclistamab in multiple myeloma with high-risk features
Published 1 month ago • 52 plays • Length 1:59Download video MP4
Download video MP3
Similar videos
-
4:03
ikema long-term sub-group analysis: isa-kd for 1q21 multiple myeloma
-
1:50
real-world outcomes of teclistamab treatment in r/r multiple myeloma
-
2:22
subgroup analysis of the panorama 1 trial of panobinostat for multiple myeloma
-
1:45
the value of teclistamab in r/r myeloma & strategies to mitigate toxicities
-
2:37
meta-analysis of studies on biomarker-defined early multiple myeloma
-
6:07
blood analysis in multiple myeloma
-
33:57
analyzing hundreds of markers in a single tumor section [webinar]
-
10:31
case study: discovery of biomarkers of immuno-oncology
-
0:59
defining the origins of multiple myeloma
-
4:05
horizon study: emd subgroup analysis
-
1:44
structural variants in multiple myeloma: impact on outcomes & potential drug targets
-
2:50
phase i study of abbv383, a novel bcmaxcd3 bispecific antibody, in r/r multiple myeloma
-
2:41
identification of myeloma high-risk subclones with single-cell technologies
-
2:20
ultra high-risk myeloma
-
1:38
the genomic definition of high-risk myeloma
-
1:53
the future of multiple myeloma treatment
-
1:22
an all-molecular diagnostic approach for myeloma
-
3:49
advances in technologies used to assess immune function in myeloma
-
1:26
insight-mm study update: treatment patterns in first and second-line multiple myeloma
-
1:37
mrd in myeloma
-
1:32
idiome: ivosidenib in idh1 mutant mds
-
2:02
rwd from insight-mm: duration of therapy and treatment sequencing